Asahi Kasei Q1 FY2027: Operating profit jumps 51.5%, all segments up

Asahi Kasei (TSE: 3407) kicked off FY2027 with broad-based strength. First-quarter revenue reached ¥826,157 million (up 11.9% YoY), while operating profit jumped 51.5% to ¥81,305 million. Ordinary profit rose 70.8% to ¥85,330 million, and net income attributable to owners of the parent soared 172.7% to ¥53,766 million. The operating margin improved to 9.8% from 7.3% a year earlier.

The top-line growth was fueled by recovering demand and successful price passthrough in the Materials segment, new drug contributions and M&A effects in Healthcare, and solid order intake in Housing. The net profit surge also reflects the absence of ¥29,880 million in business structure improvement costs recorded in the year-ago quarter. A weaker yen added ¥4,956 million in foreign exchange gains, boosting ordinary profit.

Aggregate segment profit (before corporate expenses) expanded 47.7% to ¥89,041 million (vs ¥60,275 million), underscoring the rapid strengthening of core earnings. Management left its full-year guidance unchanged: revenue ¥3,254,000 million, operating profit ¥248,000 million, net profit ¥160,000 million. First-quarter operating profit already achieved 32.8% of the annual target, raising expectations for an upward revision.

Asahi Kasei’s three reportable segments and Other business all exceeded the prior-year period.

Materials
Revenue: ¥360,158 million (+13.8% YoY) | Operating profit: ¥38,809 million (+160.4% YoY)
The Materials segment drove the overall recovery, with impairment losses and restructuring charges from the prior year fading away. Automotive engineering plastics and electronic materials saw healthy demand and successful price negotiations. The operating margin climbed to 10.8%, making it the largest profit contributor.

Housing
Revenue: ¥267,560 million (+3.3% YoY) | Operating profit: ¥20,176 million (−9.7% YoY)
Higher sales were offset by surging material costs, squeezing profit. Order backlogs remained firm, particularly for detached houses, as the company emphasizes high-value-added products. Improving margins will be a key task.

Healthcare
Revenue: ¥190,787 million (+23.0% YoY) | Operating profit: ¥29,760 million (+31.4% YoY)
Growth was propelled by the April 2026 acquisition of Germany’s Aicuris Anti-infective Cures AG and strong sales of new pharmaceuticals. The operating margin held at a high 15.6%, even as goodwill amortization weighed.

Other
Revenue: ¥7,652 million (−0.8% YoY) | Operating profit: ¥296 million (−18.5% YoY)
The small impact from plant and environmental engineering was negligible.

Asahi Kasei kept its FY2027 forecasts unchanged from the May 12, 2026 announcement. It projects revenue of ¥3,254,000 million (up 5.8% YoY), operating profit of ¥248,000 million (up 7.3%), ordinary profit of ¥247,500 million (up 7.4%), and net income of ¥160,000 million (up 0.8%). For the cumulative first half, it newly disclosed a revenue target of ¥1,686,000 million and operating profit of ¥145,000 million.

With first-quarter operating profit reaching 32.8% of the full-year target, the pace is well ahead of plan. However, the company cited the need to monitor currency swings, raw material prices, and the full-year impact of goodwill amortization from the Aicuris deal. It intends to reassess guidance at the Q2 announcement (scheduled for October 2026). Markets increasingly expect an upward revision if the Materials recovery and Healthcare synergies persist.

Total assets at end-Q1 stood at ¥4,456,791 million, up ¥318,848 million from the prior fiscal year-end. The increase mainly came from the Aicuris acquisition, which added goodwill of ¥44,573 million (provisional) and pushed intangible assets higher. Interest-bearing debt rose as the company tapped short-term borrowings, commercial paper, and bonds to fund the deal. The equity ratio dipped to 47.5% (from 50.5%), a temporary effect of the acquisition, with financial soundness maintained.

Operating cash flow was a positive ¥14,254 million (vs ¥16,660 million). Higher pretax profit was offset by a ¥73,250 million increase in inventories and a decline in accrued expenses. Investing cash flow was negative ¥195,535 million, largely due to ¥131,681 million spent on the Aicuris acquisition. Financing cash flow was positive ¥185,969 million, reflecting debt raised for the purchase. Cash and cash equivalents ended the quarter at ¥382,805 million, slightly above the prior year-end.

For shareholder returns, the company plans a ¥2 annual dividend increase to ¥44 per share (interim ¥22, year-end ¥22). It also bought back ¥17,861 million of its own shares during the quarter, signaling management’s confidence in the stock’s value.

On April 17, 2026, Asahi Kasei completed the acquisition of Aicuris Anti-infective Cures AG, a German anti-infective drug developer, along with five subsidiaries. The purchase price was not disclosed, but the deal added ¥44,573 million in goodwill (provisional) and increased segment assets by ¥160,325 million. The acquisition immediately lifted Healthcare revenue by 23.0% and operating profit by 31.4%, more than absorbing the associated amortization burden.

Aicuris brings a pipeline focused on anti-infectives, including a cytomegalovirus treatment, and strengthens Asahi Kasei’s global healthcare portfolio. Successful post-merger integration will be critical to realizing synergies and sustaining the profit contribution.

Qualitative disclosures highlight several risk factors:

• Currency risk: While the weak yen provided a tailwind, a sharp appreciation could hit export profitability and overseas earnings.
• Raw material prices: Naphtha and timber cost increases could pressure margins in Materials and Housing.
• M&A-related risk: The large goodwill from the Aicuris deal is subject to possible impairment, and integration may not deliver planned synergies.
• Macro uncertainty: A global slowdown or choppy auto/electronics demand directly affects the Materials business, with China’s economy an additional watchpoint.
• Competitive landscape: Intense global development races in healthcare mean pipeline success is not guaranteed.

The company aims to mitigate these through raw material price adjustment clauses, production optimization, and focused R&D, but agility in the face of external shifts remains essential.